#HVO hVIVO PLC – £2m hMPV characterisation study contract February 17, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing early-stage Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that, following the success of its pilot human metapneumovirus (“hMPV”) characterisation trial announced in January 2025, it has signed a £2 million contract with a new biopharmaceutical client to complete the final stage of the characterisation study ahead of future hMPV human challenge trials (“HCTs”).   The pilot characterisation trial produced a safe, measurable…

Continue reading